News & Views
Latest News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda Therapeutics receives FDA IND clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore. Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across multiple tumour types
Sign up for more news
Thank you